ACR 2020 - RA Highlights Brochure

Monday, November 9, 2020
POSTER SESSION D • 09:00 – 11:00
Imaging of Rheumatic Diseases Poster
1551 Rapid Effect of Tofacitinib in Reducing US Joint and
Tendon Inflammatory Lesions of RA Patients: Data
from a 24 Weeks Longitudinal Study
RA – Diagnosis, Manifestations, &
Outcomes Poster IV: Lifespan of a Disease
1728 Patient-Reported Outcomes of Upadacitinib versus
Abatacept in Patients with Rheumatoid Arthritis
and an Inadequate Response to Biologic
Disease-Modifying Antirheumatic Drugs:
12-Week Results of a Phase 3 Study
1749 Efficacy of Filgotinib in Patients with Rheumatoid
Arthritis with Poor Prognostic Factors:
Post Hoc Analysis
1752 Prediction of Responder and Non-responder to JAK
Inhibitors in Patients with Rheumatoid Arthritis:
A Pilot Study with Integrative Cluster Analysis
1763 Blending Hierarchical Cluster Analysis and
Cluster-Specific Regressions to Predict Clinical
Outcome to Tofacitinib Treatment in Patients with
Rheumatoid Arthritis
ABSTRACT SESSION • 10:00 – 10:50
RA – Treatments I: Maximizing Health in RA
1996 Evaluation of Response to Pneumococcal
Vaccination in Patients with Rheumatoid Arthritis
Receiving Upadacitinib: Results from a Phase 2
Open-Label Extension Study
1997 Immunogenicity of Adjuvanted Herpes Zoster
Subunit Vaccine in Rheumatoid Arthritis Patients
Treated with Janus Kinase Inhibitors and Controls:
Preliminary Results
ABSTRACT SESSION • 15:00 – 15:50
RA – Treatments II: Potential Harms &
Adverse Events
2002 Incidence and Risk Factors for Herpes Zoster
in Rheumatoid Arthritis Patients Receiving
Upadacitinib
Chairman’s picks